TY - JOUR
T1 - Vaccine injection site matters
T2 - Qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model
AU - Ohlfest, John R.
AU - Andersen, Brian M.
AU - Litterman, Adam J.
AU - Xia, Junzhe
AU - Pennell, Christopher A.
AU - Swier, Lauryn E.
AU - Salazar, Andres M.
AU - Olin, Michael R.
PY - 2013/1/15
Y1 - 2013/1/15
N2 - Malignant gliomas are lethal brain tumors for which novel therapies are urgently needed. In animal models, vaccination with tumor-associated Ags efficiently primes T cells to clear gliomas. In clinical trials, cancer vaccines have been less effective at priming T cells and extending survival. Generalized immune suppression in the tumor draining lymph nodes has been documented in multiple cancers. However, a systematic analysis of how vaccination at various distances from the tumor (closest to farthest) has not been reported. We investigated how the injection site chosen for vaccination dictates CD8 T cell priming and survival in an OVA-transfected murine glioma model. Glioma-bearing mice were vaccinated with Poly:ICLC plus OVA protein in the neck, hind leg, or foreleg for drainage into the cervical, inguinal, or axillary lymph nodes, respectively. OVA-specific CD8 T cell number, TCR affinity, effector function, and infiltration into the brain decreased as the vaccination site approached the tumor. These effects were dependent on the presence of the tumor, because injection site did not appreciably affect CD8 T cell priming in tumor-free mice. Our data suggest the site of vaccination can greatly impact the effectiveness of cancer vaccines. Considering that previous and ongoing clinical trials have used a variety of injection sites, vaccination site is potentially a critical aspect of study design that is being overlooked.
AB - Malignant gliomas are lethal brain tumors for which novel therapies are urgently needed. In animal models, vaccination with tumor-associated Ags efficiently primes T cells to clear gliomas. In clinical trials, cancer vaccines have been less effective at priming T cells and extending survival. Generalized immune suppression in the tumor draining lymph nodes has been documented in multiple cancers. However, a systematic analysis of how vaccination at various distances from the tumor (closest to farthest) has not been reported. We investigated how the injection site chosen for vaccination dictates CD8 T cell priming and survival in an OVA-transfected murine glioma model. Glioma-bearing mice were vaccinated with Poly:ICLC plus OVA protein in the neck, hind leg, or foreleg for drainage into the cervical, inguinal, or axillary lymph nodes, respectively. OVA-specific CD8 T cell number, TCR affinity, effector function, and infiltration into the brain decreased as the vaccination site approached the tumor. These effects were dependent on the presence of the tumor, because injection site did not appreciably affect CD8 T cell priming in tumor-free mice. Our data suggest the site of vaccination can greatly impact the effectiveness of cancer vaccines. Considering that previous and ongoing clinical trials have used a variety of injection sites, vaccination site is potentially a critical aspect of study design that is being overlooked.
UR - http://www.scopus.com/inward/record.url?scp=84872184215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872184215&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1201557
DO - 10.4049/jimmunol.1201557
M3 - Article
C2 - 23248259
AN - SCOPUS:84872184215
SN - 0022-1767
VL - 190
SP - 613
EP - 620
JO - Journal of Immunology
JF - Journal of Immunology
IS - 2
ER -